Publikationen in Zusammenarbeit mit Forschern von Hospital General de Granollers (19)

2023

  1. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  2. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 9, pp. 755-762

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases*

    British Journal of Dermatology, Vol. 186, Núm. 1, pp. 142-152

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Real world patient-reported outcomes in HIV-infected adults switching to EVIPLERA®, because of a previous intolerance to cART. PRO-STR study

    Current HIV Research, Vol. 16, Núm. 6, pp. 425-435

2016

  1. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

  2. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT

    Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97

2010

  1. Power doppler ultrasonography assessment of entheses in spondyloarthropathies: Response to therapy of entheseal abnormalities

    Journal of Rheumatology, Vol. 37, Núm. 10, pp. 2110-2117

2009

  1. Sustained ventricular arrhythmias in unstable angina patients: Results of the ARIAM database

    Medical Science Monitor, Vol. 15, Núm. 6

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2006

  1. Bloqueo auriculoventricular en la angina inestable. Resultados del registro ARIAM

    Medicina Intensiva, Vol. 30, Núm. 9, pp. 432-439

  2. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1

2004

  1. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals

    Infection Control and Hospital Epidemiology, Vol. 25, Núm. 10, pp. 819-824

  2. Type 1 Integrons in Epidemiologically Unrelated Acinetobacter baumannii Isolates Collected at Spanish Hospitals [3]

    Antimicrobial Agents and Chemotherapy